Clinical Trials

UVA Health System frequently opens new clinical trials, offering your patients the latest investigational treatments.

For a complete list of active cancer trials and study coordinator contact information, visit our newly launched Find a Clinical Trial website. If you have patients who may be eligible to participate in a cancer clinical trial, please email




New Trials Available at UVA

Transplant (IRB-HSR #20915)

A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord Blood for Patients with Hematological Malignancies (NCT02730299)

Primary Investigator: Leonid Volodin

B-cell Acute Lymphoblastic Leukemia (IRB-HSR #21417)

Phase I Study of Inotuzumab Ozogamicin with 3 and 4 Drug Augmented Berlin-Frankfurt-M├╝nster (BFM) Re-Induction for Younger Adults Ages 18-55 with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) (NCT03962465)

Primary Investigator: Michael Douvas

Clinical Research Coordinator: Cara Hanby

Genitourinary Oncology (IRB-HSR #21450)

A Multicenter Phase II Study Testing the Activity of Olaparib and AZD6738 (ATR Inhibitor) in Metastatic Castration-Resistant Prostate Cancer (NCT03787680)

Primary Investigator: Michael Devitt

Clinical Research Coordinator: Julio Torres

Melanoma (IRB-HSR #21850)

Pilot Evaluation of Focused Ultrasound Ablation and Focused Ultrasound Ablation Plus PD-1 Antibody Blockade in Advanced Solid Tumors (NCT04116320)

Primary Investigator: Lynn Dengel

Clinical Research Coordinator: Rachael Reed

Colorectal Cancer (IRB-HSR #21923)

A Phase Ib/2, Open-Label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-Line Therapy in Metastatic Microsatellite-Stable Colorectal Cancer (COLUMBIA-1) (NCT04068610)

Primary Investigator: Matthew Reilley

Clinical Research Coordinator: Sallie Mannen

Breast Oncology (IRB-HSR #21822)

COX Inhibition and Biomarkers of Response During Neoadjuvant Chemoendocrine Therapy for Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Stage I-III Breast Cancer (NCT04038489)

Primary Investigator: Patrick Dillon

Clinical Research Coordinator: Jake Boyd

Hematologic Malignancies IRB-HSR #21776

Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age. PrECOG Protocol Number: PrE0405. (NCT03834688)

Primary Investigator: Craig Portell

Thoracic Oncology (IRB-HSR #21811)

Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 and a CTLA-4 inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects with Non-small Cell Lung Cancer or Urothelial Cancer (NCT03989362)

Primary Investigator: Ryan Gentzler

Clinical Research Coordinator: Gracie Hockenberry


Thoracic Oncology (IRB-HSR #21913)

A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study) (NCT03971474)

Primary Investigator: Richard Hall

Clinical Research Coordinator: Gracie Hockenberry

Dementia with Lewy Bodies (IRB-HSR #21673)

EIP19-NFD-501: A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of the Oral P38 Alpha Kinase Inhibitor Neflamapimod in Dementia with Lewy Bodies (DLB) (NCT04001517)

Primary Investigator: Binit Shah

Clinical Research Coordinator: Colleen Webber